专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2003014294A2 TACIS AND BR3 POLYPEPTIDES AND USES THEREOF 审中-公开
标题翻译： TACIS和BR3多肽及其用途
公开(公告)号：WO2003014294A2
公开(公告)日：2003-02-20
申请号：PCT/US2002/023487
申请日：2002-07-24
申请人： GENENTECH, INC. , DIXIT, Vishva , GREWAL, Iqbal , RIDGWAY, John , YAN, Minhong
发明人： DIXIT, Vishva , GREWAL, Iqbal , RIDGWAY, John , YAN, Minhong
IPC分类号： C12N
CPC分类号： C07K16/2878 , A61K38/00 , C07K14/7151
摘要： Novel receptors, referred to herein as "TACIs" and "BR3", agonists and antagonists thereof, and methods of using TACIs and BR3, as well as agonists or antagonists thereof, to modulate for example, activity of tumor necrosis factor (TNF) and TNFR-related molecules, including members of the TNF and TNFR families referred to as TALL-1, APRIL, TACI, and BCMA, are provided. Methods for in vitro, in situ, and/or in vivo diagnosis and/or treatment of mammalian cells or pathological conditions associated with such TNF and TNFR-related molecules are further provided.
摘要翻译：本文称为“TACI”和“BR3”的新型受体，其激动剂和拮抗剂，以及使用TACI和BR3以及其激动剂或拮抗剂的方法来调节肿瘤坏死因子（TNF）的活性和提供TNFR相关分子，包括称为TALL-1，APRIL，TACI和BCMA的TNF和TNFR家族的成员。还提供了用于体外，原位和/或体内诊断和/或治疗与这种TNF和TNFR相关分子相关的哺乳动物细胞或病理状况的方法。

12. 发明申请

WO1997046662A1 INTERLEUKIN-1 BETA CONVERTING ENZYME LIKE APOPTOTIC PROTEASE-7 审中-公开
标题翻译： INTERLEUKIN-1转化酶类似APOPTOTIC PROTEASE-7
公开(公告)号：WO1997046662A1
公开(公告)日：1997-12-11
申请号：PCT/US1996009563
申请日：1996-06-05
申请人： SMITHKLINE BEECHAM CORPORATION , HUMAN GENOME SCIENCES, INC. , DIXIT, Vishva, M. , KIKLY, Kristine, K. , NI, Jian , ROSEN, Craig, A. , RUBEN, Steven, M.
发明人： SMITHKLINE BEECHAM CORPORATION , HUMAN GENOME SCIENCES, INC.
IPC分类号： C12N01/11
CPC分类号： C12N9/6475 , A61K38/00
摘要： Human ICE LAP-7 polypeptides and DNA (RNA) encoding such ICE LAP-7 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such ICE LAP-7 for the treatment of a susceptibility to viral infection, tumorogenesis and to diseases and defects in the control embryogenesis and tissue homeostasis, and the nucleic acid sequences described above may be employed in an assay for ascertaining such susceptibility. Antagonists against such ICE LAP-7 and their use as a therapeutic to treat Alzheimer's disease, Parkinson's disease, rheumatoid arthritis, septic shock, sepsis, stroke, chronic inflammation, acute inflammation, CNS inflammation, osteoporosis, ischemia reperfusion injury, cell death associated with cardiovascular disease, polycystic kidney disease, apoptosis of endothelial cells in cardiovascular disease, degenerative liver disease, MS, ALS, cererbellar degeneration, ischemic injury, myocardial infarction, AIDS, myelodysplastic syndromes, aplastic anemia, male pattern baldness, and head injury damage are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the interleukin-1 beta converting enzyme apoptosis proteases and for detecting altered levels of the polypeptide in a host.
摘要翻译：公开了人类ICE LAP-7多肽和编码这种ICE LAP-7的DNA（RNA）和通过重组技术产生这种多肽的方法。还公开了利用这种ICE LAP-7来治疗对病毒感染，肿瘤发生的易感性以及控制胚胎发生和组织稳态中的疾病和缺陷的方法，并且上述核酸序列可用于确定这种敏感性。对抗这种ICE LAP-7的拮抗剂及其作为治疗性阿尔茨海默病，帕金森病，类风湿性关节炎，败血性休克，败血症，中风，慢性炎症，急性炎症，CNS炎症，骨质疏松症，缺血再灌注损伤，与心血管疾病，多囊肾病，心血管疾病中的内皮细胞凋亡，退行性肝病，MS，ALS，小脑变性，缺血性损伤，心肌梗死，AIDS，骨髓增生异常综合征，再生障碍性贫血，男性型秃发和头部损伤也是披露。还公开了用于检测与核酸序列中的突变和多肽的改变的浓度相关的疾病的诊断测定。还公开了用于检测编码白细胞介素-1β转换酶凋亡蛋白酶的多核苷酸中的突变并用于检测宿主中多肽的改变水平的诊断测定法。

13. 发明申请

WO1997033904A1 DEATH DOMAIN CONTAINING RECEPTORS 审中-公开
标题翻译：包含受体的死亡域
公开(公告)号：WO1997033904A1
公开(公告)日：1997-09-18
申请号：PCT/US1996016849
申请日：1996-10-17
申请人： HUMAN GENOME SCIENCES, INC. , THE REGENTS OF THE UNIVERSITY OF MICHIGAN , YU, Guo-Liang , NI, Jian , DIXIT, Vishva, M. , GENTZ, Reiner, L. , DILLON, Patrick, J.
发明人： HUMAN GENOME SCIENCES, INC. , THE REGENTS OF THE UNIVERSITY OF MICHIGAN
IPC分类号： C07H21/04
CPC分类号： C07K14/70578 , A61K38/00
摘要： The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.
摘要翻译：本发明涉及作为肿瘤坏死因子（TNF）受体家族成员的新型死亡域含有受体（DR3和DR3-V1）蛋白。特别地，提供编码人DR3和DR3-V1蛋白的分离的核酸分子。还提供了DR3和DR3-V1多肽，载体，宿主细胞和用于制备它们的重组方法。本发明还涉及用于鉴定DR3和DR3-V1活性的激动剂和拮抗剂的筛选方法。

14. 发明申请

WO2007117763A3 METHODS AND COMPOSITIONS FOR TARGETING RELT 审中-公开
标题翻译：目标定位方法和组合
公开(公告)号：WO2007117763A3
公开(公告)日：2008-03-13
申请号：PCT/US2007061988
申请日：2007-02-12
申请人： GENENTECH INC , DIXIT VISHVA , KAYAGAKI NOBUHIKO , WU YAN
发明人： DIXIT VISHVA , KAYAGAKI NOBUHIKO , WU YAN
IPC分类号： C07K16/28 , G01N33/564 , G01N33/569 , G01N33/574 , G01N33/68
CPC分类号： G01N33/6893 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/03 , C07K14/70575 , C07K16/2878 , C07K2317/24 , C07K2317/54 , C07K2317/565 , C07K2317/75 , C07K2317/92 , C12N15/8509 , G01N33/564 , G01N33/56972 , G01N33/57492 , G01N2800/104 , G01N2800/24
摘要： Anti-RELT monoclonal antibodies, and methods for using the antibodies, are provided. Methods of using RELT polypeptides and nucleic acids in modulating immune cell development and in modulating cytokine production are also provided.
摘要翻译：提供抗RELT单克隆抗体，以及使用抗体的方法。还提供了使用RELT多肽和核酸调节免疫细胞发育和调节细胞因子产生的方法。

15. 发明申请

WO2003014294A3 TACIS AND BR3 POLYPEPTIDES AND USES THEREOF 审中-公开
公开(公告)号：WO2003014294A3
公开(公告)日：2003-02-20
申请号：PCT/US2002/023487
申请日：2002-07-24
申请人： GENENTECH, INC. , DIXIT, Vishva , GREWAL, Iqbal , RIDGWAY, John , YAN, Minhong
发明人： DIXIT, Vishva , GREWAL, Iqbal , RIDGWAY, John , YAN, Minhong
IPC分类号： C12P21/06 , C12N5/00 , C12N15/00 , C07K14/00 , A61K38/16 , C12Q1/68
摘要： Novel receptors, referred to herein as "TACIs" and "BR3", agonists and antagonists thereof, and methods of using TACIs and BR3, as well as agonists or antagonists thereof, to modulate for example, activity of tumor necrosis factor (TNF) and TNFR-related molecules, including members of the TNF and TNFR families referred to as TALL-1, APRIL, TACI, and BCMA, are provided. Methods for in vitro, in situ, and/or in vivo diagnosis and/or treatment of mammalian cells or pathological conditions associated with such TNF and TNFR-related molecules are further provided.

16. 发明申请

WO0067793A9 DEATH DOMAIN CONTAINING RECEPTOR 4 审中-公开
标题翻译：包含受体的死亡域4
公开(公告)号：WO0067793A9
公开(公告)日：2002-04-18
申请号：PCT/US0012163
申请日：2000-05-05
申请人： HUMAN GENOME SCIENCES INC , UNIV MICHIGAN , NI JIAN , ROSEN CRAIG A , PAN JAMES G , GENTZ REINER L , DIXIT VISHVA M
发明人： NI JIAN , ROSEN CRAIG A , PAN JAMES G , GENTZ REINER L , DIXIT VISHVA M
IPC分类号： G01N33/574 , A61K38/00 , A61K38/21 , A61K39/395 , A61K45/00 , A61K47/48 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/02 , C07K14/705 , C07K14/715 , C07K16/28 , C07K19/00 , C12N15/02 , C12N15/09 , C12P21/08 , C07K14/00 , C07K17/00
CPC分类号： C07K16/2878 , A61K38/00 , A61K39/39541 , C07K14/70578 , C07K14/7151 , C07K2319/30 , C12N2799/026 , A61K2300/00
摘要： The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides.
摘要翻译：本发明涉及作为肿瘤坏死因子（TNF）受体家族成员的新的含有死亡域的受体-4（DR4）蛋白。特别地，提供编码人DR4蛋白的分离的核酸分子。还提供了DR4多肽，载体，宿主细胞和用于制备它们的重组方法。本发明还涉及用于鉴定DR4活性的激动剂和拮抗剂的筛选方法以及使用DR4多核苷酸和多肽的方法。

17. 发明申请

WO0067793A8 DEATH DOMAIN CONTAINING RECEPTOR 4 审中-公开
标题翻译：包含受体的死亡域4
公开(公告)号：WO0067793A8
公开(公告)日：2001-05-25
申请号：PCT/US0012163
申请日：2000-05-05
申请人： HUMAN GENOME SCIENCES INC , UNIV MICHIGAN , NI JIAN , ROSEN CRAIG A , PAN JAMES G , GENTZ REINER L , DIXIT VISHVA M
发明人： NI JIAN , ROSEN CRAIG A , PAN JAMES G , GENTZ REINER L , DIXIT VISHVA M
IPC分类号： G01N33/574 , A61K38/00 , A61K38/21 , A61K39/395 , A61K45/00 , A61K47/48 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/02 , C07K14/705 , C07K14/715 , C07K16/28 , C07K19/00 , C12N15/02 , C12N15/09 , C12P21/08 , C07K14/00 , C07K17/00
CPC分类号： C07K16/2878 , A61K38/00 , A61K39/39541 , C07K14/70578 , C07K14/7151 , C07K2319/30 , C12N2799/026 , A61K2300/00
摘要： The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides.
摘要翻译：本发明涉及作为肿瘤坏死因子（TNF）受体家族成员的新的含有死亡域的受体-4（DR4）蛋白。特别地，提供编码人DR4蛋白的分离的核酸分子。还提供了DR4多肽，载体，宿主细胞和用于制备它们的重组方法。本发明还涉及用于鉴定DR4活性的激动剂和拮抗剂的筛选方法以及使用DR4多核苷酸和多肽的方法。

18. 发明申请

WO9625501A3 METHOD AND COMPOSITION FOR REGULATING APOPTOSIS METHOD AND COMPOSITION FOR REGULATING APOPTOSIS 审中-公开
标题翻译：用于调节疫苗方法的方法和组合物和用于调节疫苗的组合物
公开(公告)号：WO9625501A3
公开(公告)日：1996-11-14
申请号：PCT/US9601882
申请日：1996-02-09
申请人： UNIV MICHIGAN , DIXIT VISHVA M
发明人： DIXIT VISHVA M
IPC分类号： A61K38/00 , A61K48/00 , C07K14/47 , C12N15/57 , A61K38/48 , C07K14/81 , C07K16/40 , C12N5/22 , C12N9/64 , C12N15/15 , C12Q1/37
CPC分类号： C07K14/4747 , A61K38/00 , A61K48/00
摘要： This invention provides non-naturally occurring and isolated naturally occurring nucleic acid molecules which encode proteins designated Yama. This invention also provides the polypeptides and proteins encoded by these nucleic acids as well as the purified native polypeptides or proteins. Also provided by this invention is a non-naturally occurring nucleic acid molecule encoding mutant CrmA protein and a dominant inhibitory Yama. Vectors and host cells containing these nucleic acid molecules are further provided. Methods of modulating a cellular function regulated by the Fas receptor pathway in a cell is provided herein. In one aspect, this method comprises introducing into the cell a nucleic acid molecule coding for a gene product having CrmA biological activity such as dominant inhibitory Yama or alternatively, the CrmA gene product. Yama nucleic acid molecules and proteins also can be introduced into the cell to modulate the cellular function regulated by the Fas receptor.

19. 发明申请

WO1996025501A2 METHOD AND COMPOSITION FOR REGULATING APOPTOSIS 审中-公开
标题翻译：用于调节疫苗的方法和组合物
公开(公告)号：WO1996025501A2
公开(公告)日：1996-08-22
申请号：PCT/US1996001882
申请日：1996-02-09
申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN , DIXIT, Vishva, M.
发明人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN
IPC分类号： C12N15/57
CPC分类号： C07K14/4747 , A61K38/00 , A61K48/00
摘要： This invention provides non-naturally occurring and isolated naturally occurring nucleic acid molecules which encode proteins designated Yama. This invention also provides the polypeptides and proteins encoded by these nucleic acids as well as the purified native polypeptides or proteins. Also provided by this invention is a non-naturally occurring nucleic acid molecule encoding mutant CrmA protein and a dominant inhibitory Yama. Vectors and host cells containing these nucleic acid molecules are further provided. Methods of modulating a cellular function regulated by the Fas receptor pathway in a cell is provided herein. In one aspect, this method comprises introducing into the cell a nucleic acid molecule coding for a gene product having CrmA biological activity such as dominant inhibitory Yama or alternatively, the CrmA gene product. Yama nucleic acid molecules and proteins also can be introduced into the cell to modulate the cellular function regulated by the Fas receptor.
摘要翻译：本发明提供非天然存在和分离的天然存在的编码Yama蛋白质的核酸分子。本发明还提供由这些核酸编码的多肽和蛋白质以及纯化的天然多肽或蛋白质。本发明还提供编码突变体CrmA蛋白和显性抑制性Yama的非天然存在的核酸分子。进一步提供含有这些核酸分子的载体和宿主细胞。本文提供调节由细胞中Fas受体途径调节的细胞功能的方法。一方面，该方法包括向编码具有CrmA生物活性的基因产物如显性抑制性山药或者CrmA基因产物的核酸分子引入细胞。也可以将Yama核酸分子和蛋白质引入细胞以调节由Fas受体调节的细胞功能。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式